Abbott Laboratories (NYSE:ABT) Given Consensus Rating of “Moderate Buy” by Brokerages

Abbott Laboratories (NYSE:ABT) has been assigned a consensus rating of “Moderate Buy” from the twenty-six analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $118.6087.

A number of research analysts have recently issued reports on ABT shares. The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Citigroup lifted their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th.

Abbott Laboratories Trading Up 2.4%

NYSE ABT opened at $103.13 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business has a 50 day moving average price of $91.61 and a 200-day moving average price of $101.33. The company has a market cap of $179.63 billion, a price-to-earnings ratio of 33.38, a P/E/G ratio of 1.95 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period last year, the business earned $1.26 EPS. Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.51 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Insider Buying and Selling

In related news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the company. Brookmont Capital Management lifted its position in shares of Abbott Laboratories by 0.4% during the second quarter. Brookmont Capital Management now owns 37,463 shares of the healthcare product maker’s stock valued at $3,399,000 after purchasing an additional 167 shares in the last quarter. Silver Coast Investments LLC grew its position in Abbott Laboratories by 31.0% in the 2nd quarter. Silver Coast Investments LLC now owns 2,665 shares of the healthcare product maker’s stock worth $242,000 after purchasing an additional 631 shares in the last quarter. Greenwood Gearhart LLC purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $202,000. Pine Valley Investments Ltd Liability Co increased its stake in Abbott Laboratories by 2.7% in the 2nd quarter. Pine Valley Investments Ltd Liability Co now owns 44,331 shares of the healthcare product maker’s stock valued at $4,023,000 after buying an additional 1,156 shares during the last quarter. Finally, CPC Advisors LLC lifted its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. CPC Advisors LLC now owns 29,042 shares of the healthcare product maker’s stock worth $2,635,000 after buying an additional 976 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.